Allogene Therapeutics Inc

-0.14 (-2.74%)
5:01:38 PM EDT: $5.03 +0.06 (+1.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)718.15M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.01 Million
Adjusted EPS-$0.62
See more estimates
10-Day MA$5.16
50-Day MA$6.46
200-Day MA$9.89
See more pivots

Allogene Therapeutics Inc Stock, NASDAQ:ALLO

210 East Grand Avenue, South San Francisco, California 94080-4811
United States of America
Phone: +1.650.457.2700
Number of Employees: 361


Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.